Managing Cardiometabolic Risk

References

1. Després JP and Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implication for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137-59.
2. Després JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994; 8: 629-60.
3. Poston WS, 2nd and Foreyt JP. Successful management of the obese patient. Am Fam Physician 2000; 61: 3615-22.
4. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007; 176: S1-13.
5. Bray GA and Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59: 151-84.
6. Després JP, Lemieux I and Alméras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes (Lond) 2006; 30 Suppl 1: S44-52.
7. Bray GA and Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007; 132: 2239-52.
8. Després JP. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest 2006; 29: 77-82.
9. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
10. Després JP and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
11. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii-iv, 1-182.
12. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73.
13. Padwal R, Li SK and Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437-46.
14. Arbeeny CM. Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res 2004; 12: 1191-6.
15. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-211.
16. Correia ML and Haynes WG. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs 2005; 10: 643-60.
17. Shi Y and Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004; 3: 695-710.
18. Clapham JC and Arch JR. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab 2007; 9: 259-75.
19. Hauptman JB, Jeunet FS and Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55: 309S-13S.
20. McNeely W and Benfield P. Orlistat. Drugs 1998; 56: 241-9.
21. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
22. Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28: 736-44.
23. Bray GA and Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-75.
24. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69: 1108-16.
25. Padwal R, Li SK and Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003; CD004094.
26. McNeely W and Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093-124.
27. Astrup A, Hansen DL, Lundsgaard C, et al. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998; 22 Suppl 1: S30-5; discussion S6-7, S42.
28. Padwal RS and Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-7.
29. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-25.
30. Wirth A and Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-9.
31. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
32. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942-9.
33. Kim SH, Lee YM, Jee SH, et al. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116-23.
34. Nisoli E and Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26: 1027-48.
35. European agency for the evaluation of medicinal products: Committee for proprietary medicinal products opinion following an article 31 referral: sibutramine. http://www.emea.europa.eu/pdfs/human/referral/451402en.pdf. 2002.
36. Lambert DM and Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48: 5059-87.
37. Di Marzo V, Bifulco M and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
38. Di Marzo V and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
39. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
40. Carai MA, Colombo G and Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 2005; 77: 2339-50.
41. Boyd ST and Fremming BA. Rimonabant--a selective CB1 antagonist. Ann Pharmacother 2005; 39: 684-90.
42. Doyon C, Denis RG, Baraboi ED, et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403-10.
43. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
44. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
45. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29: 183-7.
46. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-305.
47. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-7.
48. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471-8.
49. Després JP, Golay A and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
50. Trujillo ME and Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-75.
51. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
52. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
53. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
54. Curioni C and Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; CD006162.
55. Després JP, Golay A and Sjöström L. Evidence that rimonabant has beneficial effects on liver enzymes in overweight/obese patients with dyslipidemia - RIO-Lipids Trial. (Abstract). Circulation 2006; 114: II-223.